Logo image of ABNX.PA

ABIONYX PHARMA SA (ABNX.PA) Stock Fundamental Analysis

EPA:ABNX - FR0012616852 - Common Stock

3.77 EUR
+0.61 (+19.12%)
Last: 9/9/2025, 7:00:00 PM
Fundamental Rating

3

Overall ABNX gets a fundamental rating of 3 out of 10. We evaluated ABNX against 70 industry peers in the Biotechnology industry. ABNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ABNX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABNX has reported negative net income.
ABNX had a negative operating cash flow in the past year.
ABNX had negative earnings in each of the past 5 years.
ABNX had a negative operating cash flow in each of the past 5 years.
ABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

ABNX has a Return On Assets (-32.35%) which is in line with its industry peers.
The Return On Equity of ABNX (-58.30%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -32.35%
ROE -58.3%
ROIC N/A
ROA(3y)-27.55%
ROA(5y)-25.53%
ROE(3y)-53.79%
ROE(5y)-48.87%
ROIC(3y)N/A
ROIC(5y)N/A
ABNX.PA Yearly ROA, ROE, ROICABNX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 18.55%, ABNX is in line with its industry, outperforming 50.00% of the companies in the same industry.
In the last couple of years the Gross Margin of ABNX has declined.
The Profit Margin and Operating Margin are not available for ABNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.52%
GM growth 5YN/A
ABNX.PA Yearly Profit, Operating, Gross MarginsABNX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

4

2. Health

2.1 Basic Checks

ABNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABNX has been increased compared to 1 year ago.
ABNX has more shares outstanding than it did 5 years ago.
ABNX has a better debt/assets ratio than last year.
ABNX.PA Yearly Shares OutstandingABNX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ABNX.PA Yearly Total Debt VS Total AssetsABNX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

An Altman-Z score of 12.24 indicates that ABNX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 12.24, ABNX belongs to the best of the industry, outperforming 88.57% of the companies in the same industry.
A Debt/Equity ratio of 0.25 indicates that ABNX is not too dependend on debt financing.
ABNX's Debt to Equity ratio of 0.25 is in line compared to the rest of the industry. ABNX outperforms 58.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 12.24
ROIC/WACCN/A
WACC7.78%
ABNX.PA Yearly LT Debt VS Equity VS FCFABNX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 1.58 indicates that ABNX should not have too much problems paying its short term obligations.
ABNX has a Current ratio (1.58) which is comparable to the rest of the industry.
ABNX has a Quick Ratio of 1.52. This is a normal value and indicates that ABNX is financially healthy and should not expect problems in meeting its short term obligations.
ABNX has a Quick ratio (1.52) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.52
ABNX.PA Yearly Current Assets VS Current LiabilitesABNX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ABNX have decreased by -7.36% in the last year.
The Revenue has decreased by -1.92% in the past year.
The Revenue has been growing by 88.92% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-7.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.56%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y88.92%
Revenue growth 5YN/A
Sales Q2Q%-12.14%

3.2 Future

Based on estimates for the next years, ABNX will show a very negative growth in Earnings Per Share. The EPS will decrease by -50.69% on average per year.
ABNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 68.05% yearly.
EPS Next Y-65.62%
EPS Next 2Y-46.84%
EPS Next 3Y-12.86%
EPS Next 5Y-50.69%
Revenue Next Year4.35%
Revenue Next 2Y19.33%
Revenue Next 3Y59.17%
Revenue Next 5Y68.05%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ABNX.PA Yearly Revenue VS EstimatesABNX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M
ABNX.PA Yearly EPS VS EstimatesABNX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABNX.PA Price Earnings VS Forward Price EarningsABNX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABNX.PA Per share dataABNX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

ABNX's earnings are expected to decrease with -12.86% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.84%
EPS Next 3Y-12.86%

More info and screens

0

5. Dividend

5.1 Amount

ABNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIONYX PHARMA SA

EPA:ABNX (9/9/2025, 7:00:00 PM)

3.77

+0.61 (+19.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)09-25 2025-09-25
Inst Owners4.67%
Inst Owner ChangeN/A
Ins Owners32.61%
Ins Owner ChangeN/A
Market Cap131.69M
Analysts85
Price Target10.97 (190.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-20.45%
EPS NY rev (3m)-20.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.94
P/FCF N/A
P/OCF N/A
P/B 17.52
P/tB 63.89
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.13
BVpS0.22
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.35%
ROE -58.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.55%
FCFM N/A
ROA(3y)-27.55%
ROA(5y)-25.53%
ROE(3y)-53.79%
ROE(5y)-48.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.52%
GM growth 5YN/A
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.3%
Cap/Sales 1.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.52
Altman-Z 12.24
F-Score4
WACC7.78%
ROIC/WACCN/A
Cap/Depr(3y)90.3%
Cap/Depr(5y)216.62%
Cap/Sales(3y)2.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.56%
EPS Next Y-65.62%
EPS Next 2Y-46.84%
EPS Next 3Y-12.86%
EPS Next 5Y-50.69%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y88.92%
Revenue growth 5YN/A
Sales Q2Q%-12.14%
Revenue Next Year4.35%
Revenue Next 2Y19.33%
Revenue Next 3Y59.17%
Revenue Next 5Y68.05%
EBIT growth 1Y-30.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-51.85%
EBIT Next 3Y-7.99%
EBIT Next 5Y-61.48%
FCF growth 1Y3.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.73%
OCF growth 3YN/A
OCF growth 5YN/A